BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

After surviving bladder cancer, beating throat cancer once, and enduring a devastating recurrence that nearly cost him his ...

enGene Holdings shares were up 7% to $3.25 after the company said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid.

The program includes pelvic exercises to improve bladder control, aerobic and strength exercise routines, and instruction on how to maintain intimacy.

The median time to treatment initiation is increasing across cancer types, and this appears to be driven by an increase in stage I cancer diagnoses, data suggest.

A new study that found a daily dose of information which helps men cope with the physical and mental distress of prostate ...

A highly expensive, revolutionary treatment for recurrent prostate cancer is for the first time in Australia available at a ...

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) ...

Transforming rural healthcare! Dr. Teresa Owens Tyson leads the Health Wagon, bringing vital diagnostic access, mobile ...

Men in high-stress, desk-bound jobs such as finance and corporate law are the fastest-growing group of patients for bladder ...